"It would be interesting to know if the hospitalization for heart failure endpoint in BETonMACE showed a differential effect with one statin or the other."
According to Google:
"According to the latest (2014) estimates from the Centers for Disease Control and Prevention (CDC), 29.1 million people, or 9.3 percent of the U.S. population, have diabetes. Type 1 diabetes affects just 5 percent of those adults, with type 2 diabetes affecting up to 95 percent. (May 8, 2017)
"The American Diabetes Association (ADA) standards of care for diabetes state that statin therapy should be initiated in individuals with diabetes and other cardiovascular risk factors with a target LDL cholesterol of <100 mg/dl."
<><><>
I suppose if hospitalization for heart failure shows little to no differential effect between statins, Apabetalone will capture a bigger diabetes market.
Koo
